{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:05:35Z","timestamp":1780347935625,"version":"3.54.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"abstract":"<jats:p>We present a single-centre retrospective case series of four patients with clinically amyopathic dermatomyositis from our institution who were treated with oral sirolimus after failing multiple other therapies. Three of our four patients achieved significant control of disease and were able to decrease their prednisone dose while on sirolimus. There were no clinically significant infections or new malignancies during sirolimus treatment in any of the patients.<\/jats:p>","DOI":"10.1093\/ced\/llae220","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:01:49Z","timestamp":1717434109000},"page":"1448-1450","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of refractory cutaneous dermatomyositis with oral sirolimus"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-0205","authenticated-orcid":false,"given":"Nakul","family":"Dar","sequence":"first","affiliation":[{"name":"School of Medicine, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L","family":"Lusa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William\u00a0C","family":"Petersen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E","family":"Greer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Hal","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Virginia , Charlottesville, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2024102416194822000_llae220-B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2017.3758","article-title":"Factors associated with clinical remission of skin disease in dermatomyositis [published correction appears in JAMA Dermatol 2018; 154:116]","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024102416194822000_llae220-B2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaad.2015.01.014","article-title":"Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology","volume":"72","author":"Fogel","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024102416194822000_llae220-B3","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2024102416194822000_llae220-B4","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024102416194822000_llae220-B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2004.\u200b05.044","article-title":"Rapamycin (sirolimus) as a steroid-\u00adsparing agent in dermatomyositis","volume":"52","author":"Nadiminti","year":"2005","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae220\/58879243\/llae220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/11\/1448\/60035549\/llae220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/11\/1448\/60035549\/llae220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:20:00Z","timestamp":1729786800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/11\/1448\/7686818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":5,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,10,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae220","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,6,3]]}}}